A comparison of the effectiveness of medium to long term biologics in moderate to severe ulcerative colitis

A comparison of the effectiveness of medium to long term biologics in moderate to severe ulcerative colitis - A comparison of the effectiveness of medium to long term biologics in moderate to severe ulcerative colitis

Status

Recruiting

Phases

Phase 3

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000038737

Enrollment

200

Registered

2019-12-01

Start date

2018-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ulcerative colitis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: moderate to severe ulcerative colitis receiving biologics

Exclusion criteria

Exclusion criteria: severe infection Patients who have undergone or consider abdominal surgery Patients who are considered ineligible

Design outcomes

Primary

Measure	Time frame
The rates of remission maintenance rates at 52 weeks, clinical activity index (partial mayo score) 2 or less	—

Secondary

Measure	Time frame
The rates of induction remission at 14 weeks, , clinical activity index (partial mayo score) 2 or less The rates of maintenance rates at 104 weeks, , clinical activity index (partial mayo score) 2 or less colectomy-free rate at 52 weeks mucosal healing rate at 52 weeks, endoscopic mayo score 0 or 1	—

Countries

Japan

Contacts

Public ContactAkihiro Yamada

Sakura medical center, Toho university internal medicine

taro-dog@sakura.med.toho-u.ac.jp0434628811

Outcome results